Drug Profile
SAR 489883
Alternative Names: SAR489883Latest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator Sanofi
- Class Antidementias; Small molecules
- Mechanism of Action EIF 2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for preclinical development in Alzheimer's-disease in France (PO)
- 16 Jul 2017 Preclinical trials in Alzheimer's disease in France (PO)
- 16 Jul 2017 Pharmacodynamics data from preclinical trials in Alzheimer's disease presented at the Alzheimer's Association International Conference 2017 (AAIC-2017)